Integrated LAMP and Immunoassay Platform Detect Diarrheal Disease
By LabMedica International staff writers Posted on 26 Sep 2018 |
Image: The SpinDx system (Photo courtesy of Sandia National Laboratories).
The challenges of diagnosing infectious disease, especially in the developing world, and the shortcomings of available instrumentation have exposed the need for portable, easy-to-use diagnostic tools capable of detecting the wide range of causative microbes while operating in low resource settings.
There are approximately 1.7 billion cases of diarrheal disease globally each year, and the syndrome is frequently caused by infections. Children are particularly vulnerable; diarrheal disease kills more than half a million children worldwide each year, and is the second leading cause of death in children under the age of five. It also represents a significant unmet diagnostic need, particularly in the developing world.
Biotechnologists at the Sandia National Laboratories (Livermore, CA, USA) have developed a syndromic test that combines immunoassays and isothermal amplification-based molecular testing. Essentially a small, fully integrated syndromic panel, the test can go from stool sample to result using the next generation of a platform developed at Sandia called SpinDx. The SpinDx system, a centrifugal microfluidics diagnostics platform with integrated sample preparation. Among other enhancements, the newest version now incorporates non-contact temperature control using a medium-wave infrared heater.
The assay can detect three protein-based enterotoxins as well as DNA of three enteric pathogens. Specifically, it detects cholera toxin, Staphylococcal enterotoxin B, and Shiga-like toxin 1, as well as Campylobacter jejuni, Escherichia coli, and Salmonella typhimurium, in less than one hour. A panel of LAMP reactions was developed for the detection of C. jejuni E. coli, and S. typhimurium. In order to determine the limit of detection of the immunoassays, toxin solutions were diluted to concentrations of 1,000, 300, 100, 30, 10, 3 and 0 ng/mL and each was run in triplicate – with the exception of the highest concentration, which was run in duplicate.
The authors concluded that the core feature of the platform enabled multiplexed detections without the burdensome complexity found in similar centrifugal microfluidic devices is the non-contact heating system. The advantages of this system, in which the heat source is spatially separate from the disc, are numerous, including the viability of a simple, low-cost disc, since features such as embedded heating elements or actuation systems for bringing a heater into contact with the disc are not needed. The study was published originally published online on August 10, 2018, in the journal Biosensors and Bioelectronics.
Related Links:
Sandia National Laboratories
There are approximately 1.7 billion cases of diarrheal disease globally each year, and the syndrome is frequently caused by infections. Children are particularly vulnerable; diarrheal disease kills more than half a million children worldwide each year, and is the second leading cause of death in children under the age of five. It also represents a significant unmet diagnostic need, particularly in the developing world.
Biotechnologists at the Sandia National Laboratories (Livermore, CA, USA) have developed a syndromic test that combines immunoassays and isothermal amplification-based molecular testing. Essentially a small, fully integrated syndromic panel, the test can go from stool sample to result using the next generation of a platform developed at Sandia called SpinDx. The SpinDx system, a centrifugal microfluidics diagnostics platform with integrated sample preparation. Among other enhancements, the newest version now incorporates non-contact temperature control using a medium-wave infrared heater.
The assay can detect three protein-based enterotoxins as well as DNA of three enteric pathogens. Specifically, it detects cholera toxin, Staphylococcal enterotoxin B, and Shiga-like toxin 1, as well as Campylobacter jejuni, Escherichia coli, and Salmonella typhimurium, in less than one hour. A panel of LAMP reactions was developed for the detection of C. jejuni E. coli, and S. typhimurium. In order to determine the limit of detection of the immunoassays, toxin solutions were diluted to concentrations of 1,000, 300, 100, 30, 10, 3 and 0 ng/mL and each was run in triplicate – with the exception of the highest concentration, which was run in duplicate.
The authors concluded that the core feature of the platform enabled multiplexed detections without the burdensome complexity found in similar centrifugal microfluidic devices is the non-contact heating system. The advantages of this system, in which the heat source is spatially separate from the disc, are numerous, including the viability of a simple, low-cost disc, since features such as embedded heating elements or actuation systems for bringing a heater into contact with the disc are not needed. The study was published originally published online on August 10, 2018, in the journal Biosensors and Bioelectronics.
Related Links:
Sandia National Laboratories
Latest Microbiology News
- Integrated Solution Ushers New Era of Automated Tuberculosis Testing
- Automated Sepsis Test System Enables Rapid Diagnosis for Patients with Severe Bloodstream Infections
- Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
- Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
- New CE-Marked Hepatitis Assays to Help Diagnose Infections Earlier
- 1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens
- Mouth Bacteria Test Could Predict Colon Cancer Progression
- Unique Metabolic Signature Could Enable Sepsis Diagnosis within One Hour of Blood Collection
- Groundbreaking Diagnostic Platform Provides AST Results With Unprecedented Speed
- Simple Blood Test Combined With Personalized Risk Model Improves Sepsis Diagnosis
- Blood Analysis Predicts Sepsis and Organ Failure in Children
- TB Blood Test Could Detect Millions of Silent Spreaders
- New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours
- New Tuberculosis Test to Expand Testing Access in Low- and Middle-Income Countries
- Rapid Test Diagnoses Tropical Disease within Hours for Faster Antibiotics Treatment
- Rapid Molecular Testing Enables Faster, More Targeted Antibiotic Treatment for Pneumonia